Consequently, these discoveries have guided the development of targeted therapies against single driver genes, including gefitinib and erlotinib for non-small-cell lung cancer patients with EGFR mutations [2], panitumumab and cetuximab for metastatic colon cancer with amplified expression of EGFR [3], vemurafenib for patients with melanomas carrying BRAF mutations [4], and crizotinib for lung cancer patients carrying EML4-ALK translocations [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.